The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 March 2026•

1 min read

Gossamer Bio Shares Plunge After Phase 3 Trial Failure; Analysts Slash Price Targets

Key Facts

1The consensus price target for Gossamer Bio declined from $4.06 a year ago to $0.77 in the past month.

2The Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing the stock to lose over 60% of its value.

Gossamer Bio (NASDAQ: GOSS) witnessed a sharp decline in its stock value following the failure of its Phase 3 PROSERA trial for seralutinib. The clinical trial failed to meet its primary endpoint, leading to a massive sell-off that wiped out over 60% of the company's market capitalization. Consequently, analysts have significantly lowered their outlook, with the consensus price target dropping from $4.06 a year ago to just $0.77 last month. Investor confidence was further shaken by the lack of detailed disclosure regarding statistical thresholds during the trial. Despite the setback, institutional and insider ownership remains high at 81.2%, suggesting some level of continued commitment from key stakeholders. The company now faces a challenging path forward as it navigates the fallout from this critical clinical disappointment and its impact on future valuation.